Douglas W Jones1, Philip P Goodney2, Brian W Nolan2, Benjamin S Brooke3, Mark F Fillinger3, Richard J Powell3, David H Stone3. 1. Department of Surgery, New York Presbyterian Hospital, Weill-Cornell Medical Center, New York, NY. Electronic address: Doj9016@nyp.org. 2. Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH; The Dartmouth Institute for Health Policy and Clinical Practice, Hanover, NH. 3. Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Abstract
OBJECTIVE: The application of thoracic endovascular aortic repair (TEVAR) has changed treatment paradigms for thoracic aortic disease. We sought to better define specific treatment patterns and outcomes for type B aortic dissection treated with TEVAR or open surgical repair (OSR). METHODS: Medicare patients undergoing type B thoracic aortic dissection repair (2000-2010) were identified by use of a validated International Classification of Diseases, Ninth Revision diagnostic and procedural code-based algorithm. Trends in utilization were analyzed by procedure type (OSR vs TEVAR), and patterns in patient characteristics and outcomes were examined. RESULTS: Total thoracic aortic dissection repairs increased by 21% between 2000 and 2010 (2.5 to 3 per 100,000 Medicare patients; P = .001). A concomitant increase in TEVAR was seen during the same interval (0.03 to 0.8 per 100,000; P < .001). By 2010, TEVAR represented 27% of all repairs. TEVAR patients had higher rates of comorbid congestive heart failure (12% vs 9%; P < .001), chronic obstructive pulmonary disease (17% vs 10%; P < .001), diabetes (8% vs 5%; P < .001), and chronic renal failure (8% vs 3%; P < .001) compared with OSR patients. For all repairs, patient comorbidity burden increased over time (mean Charlson comorbidity score of 0.79 in 2000, 1.10 in 2010; P = .04). During this same interval, in-hospital mortality rates declined from 47% to 23% (P < .001), a trend seen in both TEVAR and OSR patients. Whereas in-hospital mortality rates and 3-year survival were similar between patients selected for TEVAR and OSR, there was a trend toward women having slightly lower 3-year survival after TEVAR (60% women vs 63% men; P = .07). CONCLUSIONS: Surgical treatment of type B aortic dissection has increased over time, reflecting an increase in the utilization of TEVAR. Overall, type B dissection repairs are currently performed at lower mortality risk in patients with more comorbidities.
OBJECTIVE: The application of thoracic endovascular aortic repair (TEVAR) has changed treatment paradigms for thoracic aortic disease. We sought to better define specific treatment patterns and outcomes for type B aortic dissection treated with TEVAR or open surgical repair (OSR). METHODS: Medicare patients undergoing type B thoracic aortic dissection repair (2000-2010) were identified by use of a validated International Classification of Diseases, Ninth Revision diagnostic and procedural code-based algorithm. Trends in utilization were analyzed by procedure type (OSR vs TEVAR), and patterns in patient characteristics and outcomes were examined. RESULTS: Total thoracic aortic dissection repairs increased by 21% between 2000 and 2010 (2.5 to 3 per 100,000 Medicare patients; P = .001). A concomitant increase in TEVAR was seen during the same interval (0.03 to 0.8 per 100,000; P < .001). By 2010, TEVAR represented 27% of all repairs. TEVARpatients had higher rates of comorbid congestive heart failure (12% vs 9%; P < .001), chronic obstructive pulmonary disease (17% vs 10%; P < .001), diabetes (8% vs 5%; P < .001), and chronic renal failure (8% vs 3%; P < .001) compared with OSR patients. For all repairs, patient comorbidity burden increased over time (mean Charlson comorbidity score of 0.79 in 2000, 1.10 in 2010; P = .04). During this same interval, in-hospital mortality rates declined from 47% to 23% (P < .001), a trend seen in both TEVAR and OSR patients. Whereas in-hospital mortality rates and 3-year survival were similar between patients selected for TEVAR and OSR, there was a trend toward women having slightly lower 3-year survival after TEVAR (60% women vs 63% men; P = .07). CONCLUSIONS: Surgical treatment of type B aortic dissection has increased over time, reflecting an increase in the utilization of TEVAR. Overall, type B dissection repairs are currently performed at lower mortality risk in patients with more comorbidities.
Authors: Mark F Conrad; Emel A Ergul; Virendra I Patel; Vikram Paruchuri; Christopher J Kwolek; Richard P Cambria Journal: Ann Surg Date: 2010-10 Impact factor: 12.969
Authors: Santi Trimarchi; Christoph A Nienaber; Vincenzo Rampoldi; Truls Myrmel; Toru Suzuki; Eduardo Bossone; Valerio Tolva; Michael G Deeb; Gilbert R Upchurch; Jeanna V Cooper; Jianming Fang; Eric M Isselbacher; Thoralf M Sundt; Kim A Eagle Journal: Circulation Date: 2006-07-04 Impact factor: 29.690
Authors: Thomas T Tsai; Rossella Fattori; Santi Trimarchi; Eric Isselbacher; Truls Myrmel; Arturo Evangelista; Stuart Hutchison; Udo Sechtem; Jeanna V Cooper; Dean E Smith; Linda Pape; James Froehlich; Arun Raghupathy; James L Januzzi; Kim A Eagle; Christoph A Nienaber Journal: Circulation Date: 2006-11-13 Impact factor: 29.690
Authors: Christoph A Nienaber; Hervé Rousseau; Holger Eggebrecht; Stephan Kische; Rossella Fattori; Tim C Rehders; Günther Kundt; Dierk Scheinert; Martin Czerny; Tilo Kleinfeldt; Burkhart Zipfel; Louis Labrousse; Hüseyin Ince Journal: Circulation Date: 2009-12-07 Impact factor: 29.690
Authors: Kristina A Giles; Frank Pomposelli; Allen Hamdan; Mark Wyers; Ami Jhaveri; Marc L Schermerhorn Journal: J Vasc Surg Date: 2009-01-09 Impact factor: 4.268
Authors: Rossella Fattori; Thomas T Tsai; Truls Myrmel; Arturo Evangelista; Jeanna V Cooper; Santi Trimarchi; Jin Li; Luigi Lovato; Stephan Kische; Kim A Eagle; Eric M Isselbacher; Christoph A Nienaber Journal: JACC Cardiovasc Interv Date: 2008-08 Impact factor: 11.195
Authors: Lars G Svensson; Nicholas T Kouchoukos; D Craig Miller; Joseph E Bavaria; Joseph S Coselli; Michael A Curi; Holger Eggebrecht; John A Elefteriades; Raimund Erbel; Thomas G Gleason; Bruce W Lytle; R Scott Mitchell; Christoph A Nienaber; Eric E Roselli; Hazim J Safi; Richard J Shemin; Gregorio A Sicard; Thoralf M Sundt; Wilson Y Szeto; Grayson H Wheatley Journal: Ann Thorac Surg Date: 2008-01 Impact factor: 4.330
Authors: Nathan L Liang; Elizabeth A Genovese; Georges E Al-Khoury; Eric S Hager; Michel S Makaroun; Michael J Singh Journal: Ann Vasc Surg Date: 2016-08-10 Impact factor: 1.466
Authors: Randall R DeMartino; Indrani Sen; Ying Huang; Thomas C Bower; Gustavo S Oderich; Alberto Pochettino; Kevin Greason; Manju Kalra; Jill Johnstone; Fahad Shuja; W Scott Harmsen; Thanila Macedo; Jay Mandrekar; Alanna M Chamberlain; Salome Weiss; Philip P Goodney; Veronique Roger Journal: Circ Cardiovasc Qual Outcomes Date: 2018-08
Authors: Mario D'Oria; Indrani Sen; Courtney N Day; Jay Mandrekar; Salome Weiss; Thomas C Bower; Gustavo S Oderich; Philip P Goodney; Randall R DeMartino Journal: J Vasc Surg Date: 2020-07-30 Impact factor: 4.268